8. Ondracek CR, Frappier V, Ringel AE, et al. Mutations that allow SIR2 orthologs to function in a NAD+-depleted environment. Cell Rep, 2017, 18(10): 2310-2319.
[9]
9. Ganesan R, Hos NJ, Gutierrez S, et al. Salmonella typhimurium disrupts Sirt1/AMPK checkpoint control of mTOR to impair autophagy. Plos Pathogens, 2017, 13(2): e1006227.
[10]
10. Emamgholipour S, Hosseinnezhad A, Sahraian MA, et al. Evidence for possible role of melatonin in reducing oxidative stress in multiple sclerosis through its effect on SIRT1 and antioxidant enzymes. Life Sci, 2016, 145(8): 34-41.
[11]
11. Zhong Y, Chen AF, Zhao J, et al. Serum levels of cathepsin D, sirtuin1, and endothelial nitric oxide synthase are correlatively reduced in elderly healthy people. Aging Clin Experim Res, 2016, 28(4): 641-645.
[12]
12. Wong SY, Tang BL. SIRT1 as a therapeutic target for Alzheimer’s disease. Rev Neurosci, 2016, 27(8): 813-825.
[13]
13. Testa G, Staurenghi E, Zerbinati C, et al. Changes in brain oxysterols at different stages of Alzheimer’s disease: Their involvement in neuroinflammation. Redox Biol, 2016, 10(C): 24-33.
[14]
14. Yanagisawa S, Papaioannou AI, Papaporfyriou A, et al. Decreased Serum Sirtuin-1 in COPD. Chest, 2017, 152(2): 343-352.
[15]
15. Taka C, Hayashi R, Shimokawa K, et al. SIRT1 and FOXO1 mRNA expression in PBMC correlates to physical activity in COPD patients. Int J Chron Obstruct Pulmon Dis, 2017, 12(8): 3237-3244.
17. Cui X, Chen Q, Dong Z, et al. Inactivation of Sirt1 in mouse livers protects against endotoxemic liver injury by acetylating and activating NF-κB. Cell Death Dis, 2016, 7(10): e2403.
19. Nakamaru Y, Vuppusetty C, Wada H, et al. A protein deacetylase SIRT1 is a negative regulator of metalloproteinase-9. FASEB J, 2009, 23(9): 2810-2819.
